Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Heartless worms hold clues to cardiac arrhythmias, sudden death

20.08.2004


C. elegans model helps identify protein linked to long QT syndrome - Could help lead to development of drugs that don’t cause calcium channel block

The worm C. elegans seems an unlikely candidate for studies related to cardiac arrhythmias. After all, the microscopic organism doesn’t even have a heart.

That fact did not deter Christina I. Petersen, Ph.D., research assistant professor of Anesthesiology at Vanderbilt University Medical Center. Petersen and colleagues, including Jeffrey R. Balser, M.D., Ph.D., associate vice chancellor for Research at Vanderbilt, have now developed a C. elegans-based screening tool to identify novel protein regulators of a potassium channel involved in the rhythmic heartbeat. They report the success of their approach in the Aug. 10 issue of the Proceedings of the National Academy of Sciences. The tool could lead to ways to prevent arrhythmias and sudden death associated with block of a potassium channel called HERG (Human ether-a-go-go related gene).



Many therapeutic drugs -- antihistamines, antidepressants, antibiotics -- block HERG, Petersen said. This undesired blockade can cause acquired long QT syndrome, a disorder that puts patients at risk for life-threatening arrhythmias. It is not clear why some individuals receiving a HERG-blocking drug develop the syndrome, Petersen said. "It’s a serious problem," she said. "The FDA now requires that every drug be assayed for HERG block before it is approved." Even medicines that might be beneficial for the vast majority of patients do not make it to the market – or have been pulled from the market -- if they block HERG, Petersen said. "The pharmaceutical industry is very interested in finding ways to screen for susceptibility to acquired long QT syndrome and in discovering how to prevent it."

Other investigators have demonstrated that variations in HERG itself do not account for the majority of interindividual differences. Petersen and colleagues suspected that other proteins -- modulating factors -- are influencing HERG channel susceptibility to drug block. That’s where the worm came in. "This paper is really a proof of principle of the utility of using C. elegans to search for these HERG-interacting proteins," Petersen said.

Even though the worm doesn’t have a heart, it does have a pharynx -- a muscular tube that "pumps" food inside. The pharynx, Petersen said, is similar in many ways to a heart. It has an intrinsic beating -- like a heartbeat -- that responds to neuronal input by speeding up or slowing down.

The investigators were able to take advantage of a worm line with a mutation in the worm version of HERG. The mutation, unc-103, causes profound neuromuscular defects, including a pharyngeal pumping defect that Petersen noticed as she learned to work with the worms. "I remember the first time I saw it (the pumping defect)," she said. "It looked just like a cardiac arrhythmia." Whereas the normal worm pharynx has a rhythmic "beat" and rarely pauses, Petersen said, the unc-103 pharynx has long stretches of pauses, "as if the worms are having an arrhythmia."

The team developed a method to quantitate the pauses and demonstrated that "knocking out" the unc-103 protein using a technique called RNA interference restored normal pharyngeal pumping. The investigators reasoned that if they knocked out important HERG modulators, the effect would be the same: a restoration of rhythmic pharyngeal pumping.

To test this concept, they chose several candidate genes known to interact with HERG or other related potassium channels, knocked them out, and looked for improvements in the pumping defect. For two of the candidates, pumping improved -- the arrhythmia got better. One of these was a protein called KCR1, which Sabina Kupershmidt, Ph.D., assistant professor of Anesthesiology, and colleagues at Vanderbilt recently demonstrated prevents drug block of HERG in cardiac cells grown in the laboratory.

"We were really excited," Petersen said. "We already knew that KCR1 affected drug block of HERG in cells, and now we had data in vivo, in a living animal, that KCR1 was important for HERG function."

The investigators then turned to Ping Yang, Ph.D., research instructor and Dan M. Roden, M.D., director of the division of Clinical Pharmacology, both at Vanderbilt, to look for evidence that KCR1 impacts acquired long QT syndrome. Using a database of patients who developed acquired long QT syndrome after drug treatment, Yang was able to detect a variant in the KCR1 gene that occurred more often in control patients -- those who did not develop the syndrome.

"We suspect that this variant is protective, that patients who have it are somehow more protected against drug block of HERG compared to patients who don’t have it," Petersen said. By engineering the variant into KCR1 and studying it in cells, the researchers confirmed that drugs do not block HERG as readily when the variant KCR1 is present.

"We’re very encouraged because these studies demonstrate that you can identify a protein in the worm – which seems totally unrelated to humans -- get a phenotype in vivo, and find evidence in humans that suggests this protein is relevant to cardiac potassium channel function," Petersen said. "We speculate that KCR1 might be useful in a therapeutic context to prevent HERG block." The investigators are now using the C. elegans tool to search for novel interacting proteins that modulate HERG drug block. Any new proteins they find may have therapeutic potential for preventing acquired long QT syndrome.

In addition to Petersen, Balser, Yang, and Roden, authors of the PNAS paper include Toni R. McFarland, Svetlana Z. Stepanovic, Kenshi Hayashi, M.D., Ph.D., and Alfred L. George, M.D., at Vanderbilt and David J. Reiner, Ph.D., and James H. Thomas, Ph.D., at the University of Washington. The research was supported by the National Institutes of Health.

Balser is the James Taloe Gwathmy Clinician-Scientist and professor of Anesthesiology at Vanderbilt. Roden is the William Stokes Professor of Experimental Therapeutics and professor of Medicine and Pharmacology at Vanderbilt.

Clinton Colmenares | EurekAlert!
Further information:
http://www.vanderbilt.edu

More articles from Life Sciences:

nachricht A novel synthetic antibody enables conditional “protein knockdown” in vertebrates
20.08.2018 | Technische Universität Dresden

nachricht Climate Impact Research in Hannover: Small Plants against Large Waves
17.08.2018 | Leibniz Universität Hannover

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: It’s All in the Mix: Jülich Researchers are Developing Fast-Charging Solid-State Batteries

There are currently great hopes for solid-state batteries. They contain no liquid parts that could leak or catch fire. For this reason, they do not require cooling and are considered to be much safer, more reliable, and longer lasting than traditional lithium-ion batteries. Jülich scientists have now introduced a new concept that allows currents up to ten times greater during charging and discharging than previously described in the literature. The improvement was achieved by a “clever” choice of materials with a focus on consistently good compatibility. All components were made from phosphate compounds, which are well matched both chemically and mechanically.

The low current is considered one of the biggest hurdles in the development of solid-state batteries. It is the reason why the batteries take a relatively long...

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Quantum bugs, meet your new swatter

20.08.2018 | Information Technology

A novel synthetic antibody enables conditional “protein knockdown” in vertebrates

20.08.2018 | Life Sciences

Metamolds: Molding a mold

20.08.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>